Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
暂无分享,去创建一个
Robert Kridel | Donna Neuberg | Alessandro Pastore | Peter Möller | David M Weinstock | Oliver Weigert | Martin Dreyling | Michael Unterhalt | Wolfgang Hiddemann | Randy D Gascoyne | Wolfram Klapper | Matthew Ducar | Laurie H Sehn | Ashwini Sunkavalli | Christiane Pott | Andreas Rosenwald | Anja Mottok | A. Rosenwald | R. Gascoyne | W. Klapper | E. Hoster | L. Sehn | J. Connors | A. Mottok | D. Ennishi | R. Kridel | C. Hother | W. Hiddemann | G. Ott | H. Stein | D. Neuberg | E. Leich | H. Shulha | M. Ducar | A. Feller | M. Hansmann | P. Möller | C. Pott | M. Szczepanowski | Mark A. Murakami | D. Weinstock | A. Pastore | M. Dreyling | M. Unterhalt | O. Weigert | Joseph M Connors | Paul Van Hummelen | Daisuke Ennishi | Monika Szczepanowski | Alfred C Feller | Eva Hoster | Vindi Jurinovic | Harald Stein | German Ott | Nadja Kopp | Martin L Hansmann | Annette M Staiger | Mark Murakami | Heike Horn | Ellen Leich | Alden A Moccia | Hennady P Shulha | Christoffer Hother | V. Jurinovic | H. Horn | A. Staiger | A. Moccia | Ashwini Sunkavalli | P. Van Hummelen | Nadja Kopp
[1] A. K. Church,et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. , 2015, Blood.
[2] M. Kaminski,et al. Activating STAT6 mutations in follicular lymphoma. , 2015, Blood.
[3] W. Hiddemann,et al. How we manage follicular lymphoma , 2014, Leukemia.
[4] S. Treon,et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. , 2014, Blood.
[5] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[6] N. Harris,et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. , 2012, Blood.
[7] Sonali M. Smith. Dissecting follicular lymphoma: high versus low risk. , 2013, Hematology. American Society of Hematology. Education Program.
[8] L. Staudt,et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. , 2013, Blood.
[9] K. Basso,et al. MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma , 2013, Nature Immunology.
[10] O. Elemento,et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. , 2013, Cancer cell.
[11] Steven J. M. Jones,et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. , 2013, Blood.
[12] J. V. van Dongen,et al. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. , 2013, Methods in molecular biology.
[13] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .
[14] Yan Liu,et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.
[15] Steven J. M. Jones,et al. Recurrent targets of aberrant somatic hypermutation in lymphoma , 2012, Oncotarget.
[16] K. Tarte,et al. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis , 2012, Leukemia.
[17] Yong Jiang,et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) , 2012, Proceedings of the National Academy of Sciences.
[18] C. Sander,et al. Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.
[19] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[20] Ryan D. Morin,et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.
[21] Andrew Lister,et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.
[22] R. Gascoyne,et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. , 2010, Cancer research.
[23] R. Gascoyne,et al. Prognostic factors in follicular lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Giovanni Martinelli,et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] L. Staudt,et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. , 2007, Blood.
[26] L. Staudt,et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. , 2008, Blood.
[27] Jan Delabie,et al. Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma , 2008, Science.
[28] E. Hoster,et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect , 2006, Blood.
[29] N. Schmitz,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.
[30] P. Solal-Céligny,et al. Follicular lymphoma international prognostic index , 2006, Blood.
[31] J. Robins,et al. Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests , 2000, Biometrics.
[32] D. Weisenburger,et al. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] A. López-Guillermo,et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Ryan C. Leonard,et al. Original article: The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma , 1991 .
[35] Angela C. Dawson,et al. The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] N. S. Mcnutt,et al. B-cell lymphoma. , 1989, The Journal of dermatologic surgery and oncology.